Digestive tract tumors
Conditions
Interventions
Adebrelizumab group:The administration regimen of Adebrelizumab is intravenous drip (without prophylactic medication), 1200mg, administered once every 3 weeks.
A joint plan is provided by clinical doc
Sponsors
Dengzhou People's Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 85 Years
Inclusion criteria
Inclusion criteria: 1. Age = 18 years old, regardless of gender; 2. Patients with esophageal cancer, gastric cancer, colorectal cancer, biliary tract tumors confirmed by histology or cytology, and patients with liver cancer confirmed by imaging; 3. Patients who cannot undergo surgical resection; 4. At least measurable lesions (according to RECIST 1.1 requirements, the spiral CT scan length of the measurable lesion should be = 10mm or the short diameter of the enlarged lymph nodes should be = 15mm); 5. The researchers determined that the patient can accept the administration of adebrelimab; 6. Voluntarily participate in this study, sign an informed consent form, have good compliance, and cooperate with follow-up.
Exclusion criteria
Exclusion criteria: 1. Pregnant or lactating women; 2. Individuals who are allergic to adelbilimumab and its excipients; 3. The researcher determines other situations that are not suitable for inclusion in the study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Progression free survival;Objective Response Rate;Disease Control Rate; | — |
Secondary
| Measure | Time frame |
|---|---|
| Overall survival; | — |
Countries
China
Contacts
Public ContactKang Tairong
Dengzhou People's Hospital
Outcome results
None listed